MedTrace Logo

A Study of a New Drug Treatment for Acne

NCT01326780 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 431

Last updated 2019-10-16

Study results available
· View outcomes & findings →

Summary

A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.

Conditions

  • Acne Vulgaris

Interventions

DRUG

1.2% JNJ 10229570-AAA

1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks

DRUG

2.4% JNJ 10229570-AAA

2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks

DRUG

3.6% JNJ 10229570-AAA

3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks

OTHER

Vehicle control

Color matched cream vehicle, applied once daily to the face for 12 weeks

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson Varughese · Bausch Health Americas, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326780 on ClinicalTrials.gov